These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 22612753)

  • 1. Current immune therapies of autoimmune disease of the nervous system with special emphasis to multiple sclerosis.
    Vass K
    Curr Pharm Des; 2012; 18(29):4513-7. PubMed ID: 22612753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PML: The Dark Side of Immunotherapy in Multiple Sclerosis.
    Warnke C; Olsson T; Hartung HP
    Trends Pharmacol Sci; 2015 Dec; 36(12):799-801. PubMed ID: 26497099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunomodulatory therapies in neurologic critical care.
    McDaneld LM; Fields JD; Bourdette DN; Bhardwaj A
    Neurocrit Care; 2010 Feb; 12(1):132-43. PubMed ID: 19774497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous immunoglobulin use for neurologic diseases.
    Koski CL; Patterson JV
    J Infus Nurs; 2006; 29(3 Suppl):S21-8. PubMed ID: 16878852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune therapy for chronic inflammatory demyelinating polyneuropathy: from clinical trials to real-life.
    Rajabally YA
    Eur J Neurol; 2010 Feb; 17(2):171-2. PubMed ID: 19845752
    [No Abstract]   [Full Text] [Related]  

  • 6. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases.
    Elovaara I; Apostolski S; van Doorn P; Gilhus NE; Hietaharju A; Honkaniemi J; van Schaik IN; Scolding N; Soelberg Sørensen P; Udd B;
    Eur J Neurol; 2008 Sep; 15(9):893-908. PubMed ID: 18796075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A neurologist's guide to safe use of immunomodulatory therapies.
    Vodopivec I; Miloslavsky EM; Kotton CN; Cho TA
    Semin Neurol; 2014 Sep; 34(4):467-78. PubMed ID: 25369442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic apheresis in neurology critical care.
    Natarajan N; Weinstein R
    J Intensive Care Med; 2005; 20(4):212-25. PubMed ID: 16061904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of intravenous immunoglobulin for treatment of neurologic conditions: a systematic review.
    Fergusson D; Hutton B; Sharma M; Tinmouth A; Wilson K; Cameron DW; Hebert PC
    Transfusion; 2005 Oct; 45(10):1640-57. PubMed ID: 16181216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immunoglobulins and physiopathology: actual indications].
    Mouthon L; Guilpain P
    Rev Med Interne; 2007 May; 28 Spec No. 1():11-7. PubMed ID: 17768833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Established and novel disease-modifying treatments in multiple sclerosis.
    Cross AH; Naismith RT
    J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment in inflammatory neuropathies.
    Hutton EJ; Lunn MP
    Expert Rev Clin Immunol; 2010 Mar; 6(2):231-45. PubMed ID: 20402386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing treatment options for chronic inflammatory neuropathies and choosing the right treatment plan.
    Nobile-Orazio E; Gallia F; Terenghi F; Bianco M
    Expert Rev Neurother; 2017 Aug; 17(8):755-765. PubMed ID: 28597710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous immunoglobulin in autoimmune neuromuscular diseases.
    Dalakas MC
    JAMA; 2004 May; 291(19):2367-75. PubMed ID: 15150209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Recent acquisitions in the treatment of chronic immune-mediated polyneuropathies].
    Léger JM; Viala K
    Rev Neurol (Paris); 2004 Feb; 160(2):205-10. PubMed ID: 15034478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurologic indications for therapeutic plasma exchange: 2013 update.
    Gwathmey K; Balogun RA; Burns T
    J Clin Apher; 2014 Aug; 29(4):211-9. PubMed ID: 24890467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of intravenous immunoglobulin and plasma exchange in neurological disease.
    Linker RA; Gold R
    Curr Opin Neurol; 2008 Jun; 21(3):358-65. PubMed ID: 18451723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews.
    Clerico M; Rivoiro C; Contessa G; Viglietti D; Durelli L
    Clin Neurol Neurosurg; 2008 Nov; 110(9):878-85. PubMed ID: 18164542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutic Strategies and Disease-Modifying Therapies for Multiple Sclerosis].
    Motegi H; Kitagawa S; Nakahara J
    Brain Nerve; 2023 May; 75(5):485-490. PubMed ID: 37194517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy in multiple sclerosis, Part 2.
    Becker CC; Gidal BE; Fleming JO
    Am J Health Syst Pharm; 1995 Oct; 52(19):2105-20; quiz 2132-4. PubMed ID: 8535945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.